Acrux Limited (AU:ACR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Acrux Limited has commenced the commercial launch of its Nitroglycerin Ointment, 0.4% in the U.S., marking the company’s fourth product in the American market. This FDA-approved generic version of Rectiv® is aimed at treating chronic anal fissure pain and taps into a growing market exceeding $23 million. The launch strengthens Acrux’s strategy to expand its pipeline of topical products.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
